| Literature DB >> 31447562 |
Nasser Sharareh1, Shabnam S Sabounchi2, Mary McFarland3, Rachel Hess1.
Abstract
BACKGROUND: Opioid addiction and overdose rates are reaching unprecedented levels in the U.S., with around 47,736 overdose deaths in 2017. Many stakeholders affect the opioid epidemic, including government entities, healthcare providers and policymakers, and opioid users. Simulation and conceptual modeling can help us understand the dynamics of the opioid epidemic by simplifying the real world and informing policymakers about different health interventions that could reduce the deaths caused by opioid overdose in the United States every year.Entities:
Keywords: fentanyl; health policy; heroin; opioid; simulation and conceptual modeling
Year: 2019 PMID: 31447562 PMCID: PMC6689912 DOI: 10.1177/1178221819866211
Source DB: PubMed Journal: Subst Abuse ISSN: 1178-2218
Figure 1.PRISMA diagram, including the inclusion and exclusion process.
Summary of studies of modeling impact in development of policies to control the opioid epidemic.
| Author (reference) | Modeling method | Research area/main outcome | Key factors included | Tested or proposed scenario/strategy | Key findings through modeling or literature review |
|---|---|---|---|---|---|
| Gatley[ | System dynamics modeling | Opioid abuse through diversion and doctor shopping “visiting several doctors to obtain opioids” | Providers’ prescription of opioids, patients on short- or long-acting opioids, opioid diversion, doctor shopping, heroin users | Prescription drug monitoring program (PDMP) | 1. Opioid diversion is a major contributor to the opioid death rate. |
| Battista et al[ | Mathematical modeling | Number of people addicted to prescription opioids or in rehabilitation/treatment | Medical and nonmedical opioid use and addiction, opioid diversion, relapse | Stopping the diversion of prescribed opioids. | 1. To have an addiction-free community we need to stop prescribing opioids and diversion of prescription opioids; however, due to the availability of illicit drugs, we always face the threat of an endemic addiction. |
| Finley et al[ | Conceptual modeling | Opioid misuse and related morbidity and mortality | Outcomes related to the impact of PDMP | PDMP | 1. PDMP implementation would affect opioid prescribing behavior, diversion/doctor shopping, misuse, and morbidity/mortality. |
| Wakeland et al[ | System dynamics modeling | Opioid misuse and overdose fatalities | Medical and nonmedical opioid use and addiction, opioid diversion, providers’ perception of opioids, traffickers, chronic pain treatment | PDMP | 1. Policies affecting prescription opioid use should consider both the negative and positive outcomes of it such as overdoses against number of treated patients. |
| Aronowitz et al[ | Conceptual modeling | Number of incarcerated individuals with opioid use | The criminal justice system, incarcerated opioid users | Medication-assisted treatment (MAT) through a conceptual model of nursing and health policy | 1. MAT must be provided to prisoners who were on MAT prior to imprisonment and should be continued for those who are released. |
| Schmidt et al[ | Conceptual modeling | Key data gaps regarding pharmaceutical opioids | Medical and nonmedical opioid use and its adverse outcomes, opioid diversion | Collecting opioid-related data | New data collection is needed in the following areas to inform policy interventions: incidence diagnosis rate of chronic nonmalignant pain (CNMP), rate of opioid use to treat CNMP and its abuse rate, consume rate per each abuse, the extent of availability of opioid for nonmedical use, data on drug-seeking behaviors, fraction of diverted opioid from doctor shoppers, and amount of opioid obtained from doctor shopping or forgery. |
| Wakeland et al[ | System dynamics modeling | Nonmedical opioid users and accidental overdose mortality among them | Recreational users, opioid diversion, heroin users | Tamper-resistant drug formulations | 1. Both interventions could significantly reduce nonmedical user populations and overdose deaths in the long term. |
| Wakeland et al[ | System dynamics modeling | Medical and nonmedical opioid overdose deaths | Medical and nonmedical pharmaceutical opioid use, trafficking | Educational interventions | 1. Increasing the providers’ perceived risk of prescription opioids will raise their caution in monitoring patients with signs of abuse and eventually will reduce medical and nonmedical opioid overdose deaths. |
| Widener et al[ | Agent-based modeling | Supply side of opioids | Farmers, crops, trafficking | Economic and noneconomic incentives | 1. Applying border interventions such as trafficking blockades in all major exit points of opioid-producing countries could reduce the attractiveness of cultivating opioids. |
| Wakeland et al[ | System dynamics modeling | Abuse, addiction, and overdose death associated with the pharmaceutical opioid treatment of chronic pain | Providers’ perception of opioids, chronic pain treatment, patients on short- or long-acting and with opioid addiction | Prescriber education program | 1. Decreasing prescription rate of opioids help tamper-resistance intervention to reduce overdoses. |
| White and Comiskey[ | Mathematical modeling | Heroin users in and out of treatment | Heroin users, relapse, recruiting | Prevention strategies | 1. The rate that susceptible people become heroin users is highly affecting the recruiting rate positively. |
| Caulkins et al[ | Mathematical modeling | Occasional and heavy heroin use | Heroin users, cannabis and cocaine users | Primary prevention | 1. We cannot see the effects of an intervention on health outcome momentarily as many factors cause delays in the system. |
| Klein[ | Conceptual modeling | Future of drug policies | Drug users | Life enhancement (increasing the quality of life) | 1. Drug policies are moving towards the introduction of drug consumption rooms, social supply of drugs, and heroin-assisted therapy. |
| Agar and Reisinger[ | Conceptual modeling | Heroin use | Heroin users | Adapting trend theory to explain heroin use trends | 1. Heroin trend is a complex system and we need methods that address the complexity of it. |
Purdue Pharma L.D., a pharmaceutical company, funded these studies.
Interventions used in the studies of modeling impact in development of policies to control the opioid epidemic.
| Interventions | Target | Preventive/therapeutic |
|---|---|---|
| PDMP[ | Providers | Therapeutic |
| Provider education programs[ | Providers | Both |
| Patient education programs[ | Patients | Both |
| Tamper-resistant prescription forms, diversion control[ | Drug diversion | Both |
| Supply-side interventions[ | Illegal producers | Preventive |
| Prevention strategies[ | Patients | Preventive |
| MAT strategies[ | Patients | Therapeutic |
Funding resources for the selected articles.
| Author (reference) | Funding resource |
|---|---|
| Gatley[ | None |
| Battista et al[ | None |
| Finley et al[ | Substance Abuse Working Group of the Joint Program Committee 5/Military Operational Medicine Research Program, US Army Medical Research and Materiel Command |
| Wakeland et al[ | None |
| Aronowitz et al[ | None |
| Schmidt et al[ | Purdue Pharma L.P. |
| Wakeland et al[ | National Institute of Health/National Institute on Drug Abuse (NIDA) grant |
| Wakeland et al[ | Research grant to Portland State University funded by Purdue Pharma L.P. |
| Widener et al[ | None |
| Wakeland et al[ | Purdue Pharma L.P. |
| White and Comiskey[ | The Health Research Board of Ireland with the support of the National University of Ireland |
| Caulkins et al[ | This work was funded in part by the Robert Wood Johnson Foundation, the Qatar Foundation, the Victorian Health Promotion Foundation, and the Colonial Foundation Trust and forms part of the Drug Policy Modeling Program |
| Klein[ | None |
| Agar and Reisinger[ | NIDA |
Preventive and therapeutic interventions that either were not included in our selected articles or were not explored enough.
| Interventions | Target | Preventive/therapeutic |
|---|---|---|
| Increasing awareness of the risks associated with opioid (RX Awareness) | Public awareness | Preventive |
| Safe disposal | Drug diversion | Both |
| Controlled substance tracking and monitoring | Illegal buyers | Both |
| Needle exchange, case management, drug consumption room, social supply of drugs, heroin-assisted therapy | Opioid users | Therapeutic |
| Immunity from prosecution, naloxone over-the-counter or by prescription | Overdoses | Therapeutic |
Each intervention is targeting a different sector of the opioid epidemic.